Induction of CD4+ and CD8+ anti-tumor effector T cell responses by bacteria mediated tumor therapy

International Journal of Cancer

Volumn 137, Issue 8, 2015, Pages 2019-2028

  Stern, Christian ^a   Kasnitz, Nadine ^a   Kocijancic, Dino ^a   Trittel, Stephanie ^a   Riese, Peggy ^a   Guzman, Carlos A ^a   Leschner, Sara ^a   Weiss, Siegfried ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

CD4+; CD8+; E. coli Top10; T cells; tumor antigen presentation; tumor necrosis

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; TUMOR NECROSIS FACTOR ALPHA; GRANZYME;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIA MEDIATED CANCER THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CANCER INHIBITION; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE CLEARANCE; ESCHERICHIA COLI; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CLEARANCE; TUMOR REJECTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COLONIC NEOPLASMS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; TUMOR CELL LINE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; ESCHERICHIA COLI; FAS LIGAND PROTEIN; FEMALE; GRANZYMES; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938955776     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29567     Document Type: Article

References (36)

1. Pawelek JM, Low KB, Bermudes D., Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4: 548-56.
2. Leschner S, Weiss S., Salmonella-allies in the fight against cancer. J Mol Med (Berlin, Germany) 2010; 88: 763-73.
3. Yu YA, Zhang Q, Szalay AA., Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. Biotechnol Bioeng 2008; 100: 567-78.
4. Yu YA, Shabahang S, Timiryasova TM, et al., Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313-20.
5. Wei MQ, Mengesha A, Good D, et al., Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 2008; 259: 16-27.
6. Yazawa K, Fujimori M, Amano J, et al., Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000; 7: 269-74.
7. Fisher B, Brown A, Wolmark N, et al., Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer 1990; 66: 220-7.
8. Toso JF, Gill VJ, Hwu P, et al., Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 2002; 20: 142-52.
9. Hoffman RM., Bugging tumors. Cancer Discov 2012; 2: 588-90.
10. Kimura H, Zhang L, Zhao M, et al., Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Proliferat 2010; 43: 41-8.
11. Yam C, Zhao M, Hayashi K, et al., Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 2010; 164: 248-55.
12. Momiyama M, Zhao M, Kimura H, et al., Inhibition and eradication of human glioma with tumor-targeting Salmonella typhimurium in an orthotopic nude-mouse model. Cell Cycle (Georgetown, Tex) 2012; 11: 628-32.
13. Hayashi K, Zhao M, Yamauchi K, et al., Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 2009; 106: 992-8.
14. Hayashi K, Zhao M, Yamauchi K, et al., Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell cycle (Georgetown, Tex) 2009; 8: 870-5.
15. Zhao M, Yang M, Ma H, et al., Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006; 66: 7647-52.
16. Zhao M, Yang M, Li X-M, et al., Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-60.
17. Zhao M, Geller J, Ma H, et al., Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 2007; 104: 10170-4.
18. Forbes NS, Munn LL, Fukumura D, et al., Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 2003; 63: 5188-93.
19. Crull K, Bumann D, Weiss S., Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol 2011; 62: 75-83.
20. Leschner S, Westphal K, Dietrich N, et al., Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PloS One 2009; 4: e6692.
21. Ganss R, Ryschich E, Klar E, et al., Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62: 1462-70.
22. Den Brok MHMGM, Sutmuller RPM, Van der Voort R, et al., In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64: 4024-9.
23. Heckelsmiller K, Rall K, Beck S, et al., Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (Baltimore, Md: 1950) 2002; 169: 3892-9.
24. Avogadri F, Mittal D, Saccheri F, et al., Intra-tumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. Eur J Immunol 2008; 38: 1937-47.
25. Westphal K, Leschner S, Jablonska J, et al., Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res 2008; 68: 2952-60.
26. Paglia P, Chiodoni C, Rodolfo M, et al., Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183: 317-22.
27. Loessner H, Leschner S, Endmann A, et al., Drug-inducible remote control of gene expression by probiotic Escherichia coli Nissle 1917 in intestine, tumor and gall bladder of mice. Microbes Infect 2009; 11: 1097-105.
28. Vivier E, Tomasello E, Baratin M, et al., Functions of natural killer cells. Nat Immunol 2008; 9: 503-10.
29. Marshall NB, Swain SL., Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol 2011; 2011: 954602.
30. Perez-Diez A, Joncker NT, Choi K, et al., CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-54.
31. Quezada SA, Simpson TR, Peggs KS, et al., Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-50.
32. Gjertsen MK, Bjorheim J, Saeterdal I, et al., Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer J Int Cancer 1997; 72: 784-90.
33. Zhang S, Zhang H, Zhao J., The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys Res Commun 2009; 384: 405-8.
34. Allan S., Dendritic cells: Tailoring T-helper-cell responses. Nat Rev Immunol 2009; 9: 76.
35. Homma S, Komita H, Sagawa Y, et al., Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology 2005; 115: 451-61.
36. Hunder NN, Wallen H, Cao J, et al., Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-703.